Wound Care Business in Crisis
BioAventis has agreed to sell its wound business to LifeNet Health, which includes skin substitutes TheraSkin and TheraGenesis. The transaction includes a total cash consideration of $85 million.
Industry insights into this move
Bioventus bought Misonix, primarily for the BoneScapel product to be used in the spine. The deal also included TheraSkin, TheraGenesis, and SonicOne, a reasonably comprehensive wound portfolio.
BioAventis has agreed to sell its wound business to LifeNet Health, which includes skin substitutes TheraSkin and TheraGenesis. The transaction includes a total cash consideration of $85 million.
Why is everyone worried about the wound care market?
The problem with wound care is that it is a vastly different model than orthopedics, with a complex reimbursement structure for skin substitutes. CMS is proposing changes to the reimbursement of skin substitutes, dramatically impacting the wound care market. This change would reclassify all cellular and/or tissue-based products (CTPs) for skin wounds as “supplies incident to a physician service,” and package payment for these “supplies” into the practice expense associated with that service. This will kill the office-based skin substitute business for most orthopedic and podiatric practices.
Recent Posts
See AllDr. Ned Amendola MD, FAAOS, FRCS(C) from Duke University was named second vice president of the American Academy of Orthopedic Surgeons (AAOS) and will ascend to president in 2025-2026. Fellowship tra
As speculated in February 2023 FIX, Enovis announced early this week that it has consummated a deal for Novastep with the MIS bunion system being the prize along with access to a robust OUS sales chan
Startup capital is the fuel for innovation in foot and ankle surgery. There are several sources for capital with debt financing through banks representing one of them. Competition is good and the more
